Access to diagnostic imaging and radiotherapy technologies for patients with cancer in the Baltic countries, eastern Europe, central Asia, and the Caucasus: a comprehensive analysis

Lancet Oncology Elsevier 25:11 (2024) 1487-1495

Authors:

Manjit Dosanjh, Vesna Gershan, Eugenia C Wendling, Jamal S Khader, Taofeeq A Ige, Mimoza Ristova, Richard Hugtenburg, Petya Georgieva, C Norman Coleman, David A Pistenmaa, Gohar H Hovhannisyan, Tatul Saghatelyan, Kamal Kazimov, Rovshan Rzayev, Gulam R Babayev, Mirzali M Aliyev, Eduard Gershkevitsh, Irina Khomeriki, Lily Petriashvili, Maia Topeshashvili, Raushan Zakirova, Aigerim Rakhimova, Natalya Karnakova, Aralbaev Rakhatbek, Narynbek Kazybaev, Oksana Bondareva, Kristaps Palskis, Ga募ina Boka, Erika Korobeinikova, Linas Kudrevicius, Ion Apostol, Ludmila V Eftodiev, Alfreda Rosca, Galina Rusnac, Mukhabatsho Khikmatov, Sergii Luchkovskyi, Yuliia Severyn, Jamshid M Alimov, Munojat Ismailova, Suvsana M Talibova

Abstract:

叠补肠办驳谤辞耻苍诲:听Only 10鈥40% of patients with cancer in low-income and middle-income countries were able to access curative or palliative radiotherapy in 2015. We aimed to assess the current status of diagnostic imaging and radiotherapy services in the Baltic countries, eastern Europe, central Asia, and the Caucasus by collecting and analysing local data.

惭别迟丑辞诲蝉:听This Access to Radiotherapy (ART) comprehensive analysis used data from 12 countries: the three Baltic countries (Estonia, Latvia, and Lithuania), two countries in eastern Europe (Moldova and Ukraine), four countries in central Asia (Kazakhstan, Kyrgyzstan, Tajikistan, and Uzbekistan), and three countries in the Caucasus (Armenia, Azerbaijan, and Georgia), referred to here as the ART countries. We were not able to obtain engagement from Turkmenistan. The primary outcome was to update the extent of shortfalls in the availability of diagnostic imaging and radiotherapy technologies and radiotherapy human resources for patients with cancer in former Soviet Union countries. Following the methods of previous similar studies, we developed three questionnaires鈥攖argeted towards radiation oncologists, regulatory authorities, and researchers鈥攔equesting detailed information on the availability of these resources. Authors from participating countries sent two copies of the appropriate questionnaire to each of 107 identified institutions and coordinated data collection at the national level. Questionnaires were distributed in English and Russian and responses in both languages were accepted. Two virtual meetings held on May 30 and June 1, 2022, were followed by an in-person workshop held in Almaty, Kazakhstan, in September, 2022, attended by representatives from all participating countries, to discuss and further validate the data submitted up to this point. The data were collected on a dedicated web page, developed by the International Cancer Expert Corps, and were then extracted and analysed.

贵颈苍诲颈苍驳蝉:听Data were collected between May 10 and Nov 30, 2022. 81 (76%) of the 107 institutions contacted, representing all 12 ART countries, submitted 167 completed questionnaires. The Baltic countries, which are defined as high-income countries, had more diagnostic imaging equipment and radiotherapy human resources (eg, Latvia [1路74] and Lithuania [1路47] have a much higher number of radiation oncologists per 100 000 population than the other ART countries, all of which had <1 radiation oncologist per 100 000 population) and greater radiotherapy technological capacities (higher numbers of linear accelerators and, similar to Georgia, high total external beam radiotherapy capacity) than the other ART countries, as well as high cancer detection rates (Latvia 311 cases per 100鈥000 population, Lithuania 292, and Estonia 288聽vs, for example, 178 in Armenia, 144 in Ukraine, and 72 in Kazakhstan) and low cancer mortality-to-cancer incidence ratios (Estonia 0路43, Latvia 0路49, and Lithuania 0路48; lower than all but Kazakhstan [0路41]). The highest cancer mortality-to-cancer incidence ratios were reported by Moldova (0路71) and Georgia (0路74).

滨苍迟别谤辫谤别迟补迟颈辞苍:听Our findings show that the number of cancer cases, availability of diagnostic imaging equipment, radiation oncologists and radiotherapy capacity, and cancer mortality-to-cancer incidence ratios all vary substantially across the countries studied, with the three high-income, well resourced Baltic countries performing better in all metrics than the included countries in eastern Europe, central Asia, and the Caucasus. These data highlight the challenges faced by many countries in this study, and might help to justify increased investment of financial, human, and technological resources, with the aim to improve cancer treatment outcomes.

贵耻苍诲颈苍驳:听US Department of Energy's National Nuclear Security Administration's Office of Radiological Security.

Global Workforce and Access: Demand, Education, Quality

Seminars in Radiation Oncology Elsevier 34:4 (2024) 477-493

Authors:

Surbhi Grover, Laurence Court, Sheldon Amoo-Mitchual, John Longo, Danielle Rodin, Aba Anoa Scott, Yolande Lievens, Mei Ling Yap, May Abdel-Wahab, Peter Lee, Ekaterina Harsdorf, Jamal Khader, Xun Jia, Manjit Dosanjh, Ahmed Elzawawy, Taofeeq Ige, Miles Pomper, David Pistenmaa, Patricia Hardenbergh, Daniel G Petereit, Michele Sargent, Kristin Cina, Benjamin Li, Yavuz Anacak, Chuck Mayo, Sainikitha Prattipati, Nwamaka Lasebikan, Katharine Rendle, Donna O'Brien, Eugenia Wendling, C Norman Coleman

Radiotherapy and theranostics: a Lancet Oncology Commission

Lancet Oncology Elsevier 25:11 (2024) e545-e580

Authors:

May Abdel-Wahab, Francesco Giammarile, Mauro Carrara, Diana Paez, Hedvig Hricak, Nayyereh Ayati, Jing Jing Li, Malina Mueller, Ajay Aggarwal, Akram Al-Ibraheem, Sondos Alkhatib, Rifat Atun, Abubakar Bello, Daniel Berger, Roberto C Delgado Bolton, John M Buatti, Graeme Burt, Olivera Ciraj Bjelac, Lisbeth Cordero-Mendez, Manjit Dosanjh, Thomas Eichler, Elena Fidarova, Soehartati Gondhowiardjo, Mary Gospodarowicz, Surbhi Grover, Varsha Hande, Ekaterina Harsdorf-Enderndorf, Ken Herrmann, Michael S Hofman, Ola Holmberg, David Jaffray, Peter Knoll, Jolanta Kunikowska, Jason S Lewis, Yolande Lievens, Miriam Mikhail-Lette, Dennis Ostwald, Jatinder R Palta, Platon Peristeris, Arthur A Rosa, Soha Ahmed Salem, Marcos A Dos Santos, Mike M Sathekge, Shyam Kishore Shrivastava, Egor Titovich, Jean-Luc Urbain, Verna Vanderpuye, Richard L Wahl, Jennifer S Yu, Mohamed Saad Zaghloul

Abstract:

Following on from the 2015 Lancet Oncology Commission on expanding global access to radiotherapy, Radiotherapy and theranostics: a Lancet Oncology Commission was created to assess the access and availability of radiotherapy to date and to address the important issue of access to the promising field of theranostics at a global level. A marked disparity in the availability of radiotherapy machines between high-income countries and low-income and middle-income countries (LMICs) has been identified previously and remains a major problem. The availability of a suitably trained and credentialled workforce has also been highlighted as a major limiting factor to effective implementation of radiotherapy, particularly in LMICs. We investigated initiatives that could mitigate these issues in radiotherapy, such as extended treatment hours, hypofractionation protocols, and new technologies. The broad implementation of hypofractionation techniques compared with conventional radiotherapy in prostate cancer and breast cancer was projected to provide radiotherapy for an additional 2路2 million patients (0路8 million patients with prostate cancer and 1路4 million patients with breast cancer) with existing resources, highlighting the importance of implementing new technologies in LMICs. A global survey undertaken for this Commission revealed that use of radiopharmaceutical therapy-other than <sup>131</sup>I-was highly variable in high-income countries and LMICs, with supply chains, workforces, and regulatory issues affecting access and availability. The capacity for radioisotope production was highlighted as a key issue, and training and credentialling of health professionals involved in theranostics is required to ensure equitable access and availability for patient treatment. New initiatives-such as the International Atomic Energy Agency's Rays of Hope programme-and interest by international development banks in investing in radiotherapy should be 91探花ed by health-care systems and governments, and extended to accelerate the momentum generated by recognising global disparities in access to radiotherapy. In this Commission, we propose actions and investments that could enhance access to radiotherapy and theranostics worldwide, particularly in LMICs, to realise health and economic benefits and reduce the burden of cancer by accessing these treatments.

Active dosimetry for VHEE FLASH radiotherapy using beam profile monitors and charge measurements

Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment Elsevier 1069 (2024) 169845

Authors:

Vilde F Rieker, Roberto Corsini, Steinar Stapnes, Erik Adli, Wilfrid Farabolini, Veljko Grilj, Kyrre N Sjobak, Laurence M Wroe, Avni Aksoy, Cameron S Robertson, Joseph J Bateman, Pierre Korysko, Alexander Malyzhenkov, Antonio Gilardi, Manjit Dosanjh

Abstract:

The discovery of the FLASH effect has revealed a high potential for treating cancer more efficiently by sparing healthy tissue. The surge in related medical research activities over the last couple of years has triggered a demand for technology with the capability of generating and measuring ionizing radiation at ultra-high dose-rates (UHDR). A reliable dosimetry system is an integral part of a radiotherapy machine. Because existing active dosimetry methods are unable to handle the dose-rates required for FLASH, UHDR dosimetry has emerged as an important area of research. In this paper we present an active dosimetry method based on a scintillating screen and an integrating current transformer. This method provides a simultaneous measurement of the absolute dose delivery as well as the 2D dose distribution. The measurements have been correlated with corresponding readings from radiochromic films (RCFs), and a procedure for image processing has been established. Moreover, different methods of calibrating the active dosimetry system against RCFs have been introduced and evaluated. Lastly, we present results which demonstrate that an agreement with RCFs of better than 5% can be realistically expected if camera parameters are carefully optimized.

鈥淧article therapy - future for the Baltic states?鈥 鈥 synthesis of the expert workshop report

Health and Technology Springer 14:5 (2024) 965-972

Authors:

Kristaps Pa募skis, Erika Korobeinikova, Dace Bogorada-Saukuma, Anna Maria Camarda, Rebecca Taylor, Elena Benedetto, Edgars Mamis, Maija Radzi艈a, Andrejs 膾rglis, Diana Adliene, Manjit Dosanjh, Maurizio Vretenar, Toms Torims

Abstract:

Background: Baltic States remains one of the few regions in the Europe without a dedicated particle therapy center. An initiative since 2021 has been started by CERN Baltic Group on a novel particle therapy center development in the region in partnership with CERN NIMMS collaboration. With a conceptual design idea in early 2022 and stakeholder engagement activities in late 2022 - next step forward was necessary for the initiative for a more in-depth analysis. Methods: A dedicated workshop 鈥淧article therapy - future for the Baltic States? State-of-play, synergies and challenges鈥 was held. The workshop was attended by medical community from the Baltics, as well as CERN technical experts and particle therapy practicing clinicians, with scientific programme split in 5 main areas of investigation. Results: Current cancer epidemiology statistics and RT technological possibilities in the region were analyzed, with first estimates of eligible number of patients calculated. Technological development level of the proposed accelerator complex was discussed, as well the clinical needs and synnergy possibilities with the nuclear medicine field. Conclusions: The current state and calculated first estimates presented here have shown a promising starting point, which prompts even further in-depth work 鈥 a feasibility study for development of a novel particle therapy center in the Baltic States.